• Donate
  • Login
Tuesday, December 9, 2025
  • Login
  • Register
Canary
Cart / £0.00

No products in the basket.

MEDIA THAT DISRUPTS
  • UK
  • Global
  • Opinion
  • Skwawkbox
  • Manage Subscription
  • Support
  • Features
    • Health
    • Environment
    • Science
    • Feature
    • Sport & Gaming
    • Lifestyle
    • Tech
    • Business
    • Money
    • Travel
    • Property
    • Food
    • Media
No Result
View All Result
MANAGE SUBSCRIPTION
SUPPORT
  • UK
  • Global
  • Opinion
  • Skwawkbox
  • Manage Subscription
  • Support
  • Features
    • Health
    • Environment
    • Science
    • Feature
    • Sport & Gaming
    • Lifestyle
    • Tech
    • Business
    • Money
    • Travel
    • Property
    • Food
    • Media
No Result
View All Result
Canary
No Result
View All Result

Three pharma firms accused of collusion over NHS drug supply

The Canary by The Canary
3 October 2019
in Other News & Features, UK
Reading Time: 2 mins read
169 3
A A
3
Home Other News & Features
Share on FacebookShare on TwitterShare on BlueskyShare via WhatsAppShare via TelegramShare on Threads

Three drug firms have been found provisionally guilty by the competition watchdog of colluding over the supply of a life-saving treatment for thousands of patients on the NHS.

The Competition and Markets Authority (CMA) said it believes pharmaceutical firm Aspen paid two rivals – Amilco and Tiofarma – to stay out of the market for fludrocortisone acetate tablets – a treatment for Addison’s disease.

Aspen’s actions protected its UK monopoly over the supply of the drug to the NHS and gave the firm the opportunity to increase prices by up to 1,800%, the CMA said.

In exchange, it is alleged that Tiofarma was made the sole manufacturer of fludrocortisone for direct sale in the UK, and Amilco received a 30% share of the increased prices that Aspen was able to charge.

Aspen has admitted its part in the collusion and will pay £8m to the NHS as part of a settlement, as well as up to a further £2.1m if the CMA ultimately concludes competition law has been broken.

It marks the first time a CMA probe has secured a payment to the NHS.

Aspen has also committed to ensure there will be at least two suppliers of fludrocortisone in the UK to help the NHS access more competitive prices.

But Amilco and Tiofarma have yet to admit their part in the alleged illegal market-sharing.

They now have the opportunity to respond to the CMA’s provisional findings.

Michael Grenfell, the CMA’s executive director of enforcement, said: “The NHS should not be denied the opportunity of benefiting from an increased choice of suppliers, and so potential savings on what it spends on essential drugs”.

Fludrocortisone is a vital treatment, on which thousands of patients depend, mainly to treat primary or secondary adrenal insufficiency, commonly known as Addison’s disease.

Aspen is a South African pharmaceutical firm, while Amilco is a British company that provides consultancy services to drug companies, and Tiofarma is a Dutch pharmaceutical manufacturer that makes products including fludrocortisone acetate.

Tags: NHS
Share128Tweet80ShareSendShareShare
Previous Post

‘Obvious challenges’ with UK exit plan, warns Irish minister

Next Post

Australians take direct action to stop a coal company ‘wrecking’ the Great Barrier Reef

Next Post
A blockade at Adani's Abbot Point coal terminal off the Great Barrier Reef

Australians take direct action to stop a coal company 'wrecking' the Great Barrier Reef

Dina Asher-Smith won gold last night. She became a true champion 24 hours earlier.

Dina Asher-Smith won gold last night. She became a true champion 24 hours earlier.

Four officers killed in knife attack at Paris police headquarters

Climate protesters arrested for spraying fake blood at Treasury over UK funding for fossil-fuel schemes

'Shameful practices of Thomas Cook's directors' could cost taxpayers at least £60m

Please login to join discussion
Israel
Analysis

Israel executes two unarmed Palestinians after they surrendered

by Charlie Jaay
28 November 2025
Palestine Action
Analysis

Disabled arrestee refuses to be silent, saying “freedom is not to be taken from us without a fight”

by Ed Sykes
28 November 2025
Syria
Analysis

Syria: Fragile peace after Bedouin murders ignite sectarian tensions

by Alex/Rose Cocker
28 November 2025
Barghouti
Skwawkbox

Video: Barghouti honoured with new mural after 24 years as Israel’s political prisoner

by Skwawkbox
28 November 2025
palestine action
Analysis

Shocking new report reveals what really drove the government’s crackdown on Palestine Action

by The Canary
28 November 2025
  • Get our Daily News Email

The Canary
PO Box 71199
LONDON
SE20 9EX

Canary Media Ltd – registered in England. Company registration number 09788095.

For guest posting, contact ben@thecanary.co

For other enquiries, contact: hello@thecanary.co

Sign up for the Canary's free newsletter and get disruptive journalism in your inbox twice a day. Join us here.

© Canary Media Ltd 2024, all rights reserved | Website by Monster | Hosted by Krystal | Privacy Settings

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
  • UK
  • Global
  • Opinion
  • Skwawkbox
  • Manage Subscription
  • Support
  • Features
    • Health
    • Environment
    • Science
    • Feature
    • Sport & Gaming
    • Lifestyle
    • Tech
    • Business
    • Money
    • Travel
    • Property
    • Food
    • Media
  • Login
  • Sign Up
  • Cart